Norman E. Sharpless, MD, Director of the National Cancer Institute, discusses his vision for the NCI in four key areas––big data, clinical trials, workforce development, and basic science––and how this vision affects the hematology community.
Gilles A. Salles, MD, PhD, of Centre Hospitalier Lyon Sud, discusses trial findings on the monoclonal antibody MOR208 combined with lenalidomide in people with relapsed or refractory diffuse large B-cell lymphoma (Abstract 227).
Steven M. Horwitz, MD, of Memorial Sloan Kettering Cancer Center, discusses phase IIa study findings on the novel SYK/JAK inhibitor cerdulatinib for relapsed/refractory peripheral T-cell lymphoma and cutaneous T-cell lymphoma (Abstract 1001).
Alok A. Khorana, MD, of the Cleveland Clinic, discusses study findings on rivaroxaban thromboprophylaxis in high-risk ambulatory patients, which showed a reduction in venous thromboembolism and related death (Abstract LBA1).
Shaji K. Kumar, MD, of the Mayo Clinic, discusses phase III findings on daratumumab plus lenalidomide and dexamethasone vs lenalidomide and dexamethasone in people with newly diagnosed multiple myeloma who are ineligible for transplant (Abstract LBA2).
Steven M. Horwitz, MD, of Memorial Sloan Kettering Cancer Center, discusses phase III findings on brentuximab vedotin and CHP vs CHOP in the front-line treatment of patients with CD30-positive peripheral T-cell lymphomas (Abstract 997).
